| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/23/2011 | EP2298355A2 Albumin fusion proteins |
| 03/23/2011 | EP2298090A1 Pharmaceutical or nutraceutical composition |
| 03/23/2011 | EP2297183A1 Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
| 03/23/2011 | EP2297100A1 Tetrahydrocyclopentaýb¨indole androgen receptor modulators |
| 03/23/2011 | EP2296652A1 Topical regional neuro-affective therapy |
| 03/23/2011 | EP1448205B1 Combinations for the treatment of immunoinflammatory disorders |
| 03/23/2011 | EP1351707B1 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 03/23/2011 | EP1278748B1 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/23/2011 | EP1140836B1 Amide compounds |
| 03/23/2011 | CN1951372B Solid oral dosage forms comprising valsartan and HCTZ |
| 03/23/2011 | CN101987847A Novel heterocyclic NF-kB inhibitors |
| 03/23/2011 | CN101987183A Chinese medicinal herb formula for treating myasthenia gravis |
| 03/23/2011 | CN101987135A Medicine for treating tetanus and preparation method thereof |
| 03/22/2011 | US7910709 Thyroid stimulating hormone for use in diagnosis, prevention and treatment of thyroid gland disorders |
| 03/22/2011 | US7910605 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders |
| 03/22/2011 | US7910123 Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent |
| 03/22/2011 | CA2615856C Use of dopamine d2/d3 receptor agonists to treat fibromyalgia |
| 03/22/2011 | CA2492342C Novel bio-active pyrimidine derivatives |
| 03/22/2011 | CA2480273C Ph-sensitive polymer |
| 03/22/2011 | CA2479363C Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
| 03/22/2011 | CA2471538C Pyrrolopyrimidines |
| 03/17/2011 | WO2011031901A1 Actriib antagonists and dosing and uses thereof |
| 03/17/2011 | WO2011030981A1 Method for preparing [18f]fallypride with low base concentration |
| 03/17/2011 | WO2011030116A1 Use of steroid compounds for inflammatory and autoimmune disorders |
| 03/17/2011 | US20110065793 Highly purified ethyl epa and other epa derivatives |
| 03/17/2011 | US20110065760 Compounds for the inhibition of rotamases and use thereof |
| 03/17/2011 | US20110065721 Metaxalone products, method of manufacture, and method of use |
| 03/17/2011 | US20110065653 Tat-utrophin as a protein therapy for dystrophinopathies |
| 03/17/2011 | US20110064762 Protein a compositions and methods of use |
| 03/17/2011 | US20110064757 Nucleic acid molecules and polypeptides for immune modulation |
| 03/17/2011 | US20110064720 Dietary Supplement Compositions and Methods of Making and Using the Same |
| 03/17/2011 | US20110064712 Dietary Supplement Compositions and Methods of Making and Using the Same |
| 03/17/2011 | CA2773600A1 Use of steroid compounds for inflammatory and autoimmune disorders |
| 03/16/2011 | EP2295550A2 Crystal structures of GSK-3beta protein and protein complexes and their use. |
| 03/16/2011 | EP2295466A2 Antibodies to myostatin |
| 03/16/2011 | EP2295456A1 Albumin fusion proteins |
| 03/16/2011 | EP2295080A2 B-cell reduction using CD37-specific and CD20-specific binding molecules |
| 03/16/2011 | EP2295063A2 Compositions and the use thereof the treatment of mitochondrial diseases |
| 03/16/2011 | EP2293793A1 2,5-disubstituted imidazo[4,5-c]pyridines for treating muscular dystrophy |
| 03/16/2011 | EP1448535B1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 03/16/2011 | CN1939324B Medical usage of periplocin A and E |
| 03/16/2011 | CN101986782A Substituted heteroarylamide diazepinopyrimidone derivatives |
| 03/15/2011 | US7906659 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 03/15/2011 | US7906650 Caspase inhibitors and uses thereof |
| 03/15/2011 | CA2468311C Benzothiazole derivatives |
| 03/15/2011 | CA2433806C Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 03/15/2011 | CA2383284C Use of ribose to prevent cramping and soreness in muscles |
| 03/15/2011 | CA2277192C Nuclear transfer with differentiated fetal and adult donor cells |
| 03/10/2011 | US20110060130 Neutralizing human anti-igfr antibody |
| 03/10/2011 | US20110060017 Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| 03/10/2011 | US20110060004 Imidazo-Pyridine Derivatives as Activin-Like Receptor Kinase (ALK4 or ALK5) Inhibitors |
| 03/10/2011 | US20110059968 Carboxamide compounds and their use as calpain inhibitors |
| 03/10/2011 | US20110059944 Certain Substituted Amides, Method of Making, and Method of Use Thereof |
| 03/10/2011 | US20110059935 Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS |
| 03/10/2011 | US20110059927 Calcium Formate For Use As A Dietary Supplement |
| 03/10/2011 | US20110059178 Tissue Engineered Meniscus Repair Composition |
| 03/10/2011 | US20110059172 Therapeutic compositions |
| 03/10/2011 | US20110059147 Long term drug delivery devices with polyurethane based polymers and their manufacture |
| 03/10/2011 | US20110059117 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same |
| 03/10/2011 | US20110059010 Dual phase drug release system |
| 03/10/2011 | CA2772191A1 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
| 03/09/2011 | EP2292771A2 Sense mRNA therapy |
| 03/09/2011 | EP2292091A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
| 03/09/2011 | EP1748069B1 Follistatin mutant polypeptide |
| 03/09/2011 | EP1497279B1 Substituted indoles and their use as 5ht-reuptake inhibitors and as 5ht ligands |
| 03/09/2011 | CN101983672A Medicament for treating cramp |
| 03/08/2011 | US7902160 ENA nucleic acid drugs modifying splicing in mRNA precursor |
| 03/08/2011 | US7901672 Methods of making enhanced, autologous fat grafts |
| 03/08/2011 | CA2468691C 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists |
| 03/08/2011 | CA2464721C Nitrogenous (tetrahydropyridyl) (alkyl) heterocycles with tnf activity |
| 03/08/2011 | CA2240516C Novel tyrosine kinase receptors and ligands |
| 03/03/2011 | WO2011025368A1 Method of treating frailty |
| 03/03/2011 | WO2011024822A1 Diagnosis marker, diagnosis method and therapeutic agent for amyotrophic lateral sclerosis, and animal model and cell model developing amyotrophic lateral sclerosis |
| 03/03/2011 | WO2010129273A3 Butaclamol for the treatment of amyotrophic lateral sclerosis |
| 03/03/2011 | WO2008053362A3 Bioresponsive polymers |
| 03/03/2011 | US20110054005 Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| 03/03/2011 | US20110053877 Nimesulide and muscle relaxant combinations thereof |
| 03/03/2011 | US20110053854 Treatment of muscular dystrophies and related disorders |
| 03/03/2011 | US20110053853 Use of copolymer 1 for treatment of muscular dystrophy |
| 03/03/2011 | US20110052730 Leaves Extract of Panax sp., a Process of Making the Same and Uses Thereof |
| 03/03/2011 | US20110052729 Pharmaceutical or nutraceutical composition |
| 03/03/2011 | US20110052556 Pharmaceutical composition comprising racetam and carnitine and process for its preparation |
| 03/03/2011 | CA2759815A1 Method of treating frailty |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289555A1 Method of treating frailty |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289519A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 03/02/2011 | EP2289503A2 Treating muscle wasting with selective androgen receptor modulators |
| 03/01/2011 | US7897757 for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes and any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue |
| 03/01/2011 | US7897731 Corticotropin releasing factor 2 receptor agonists |
| 03/01/2011 | US7897729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors |
| 03/01/2011 | US7897180 Enamel matrix protein composition for treatment of systemic inflammatory response |
| 03/01/2011 | US7897157 Polypeptides with a functional binding domain, translocation domain, a therapeutic domain and a non-native protease cleavage site for cleavage in vitro following expression as a single chain; efficient, less dangerous production method; botulinum neurotoxins targeted to specific cell types |
| 02/24/2011 | WO2011022491A1 Cysteine for physiological injection |
| 02/24/2011 | WO2011021678A1 Fused heterocyclic compound |
| 02/24/2011 | WO2011020874A1 Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| 02/24/2011 | WO2010136508A3 Stem cell targeting |
| 02/24/2011 | US20110046360 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR |
| 02/24/2011 | US20110046223 Treatment of neurofibromatosis |
| 02/24/2011 | US20110046203 Antisense oligonucleotides for inducing exon skipping and methods of use thereof |